The complex patent situation regarding antibody Fc engineering.

Fc domain engineering enables precise modulation of antibody effector functions, serum half-life, conjugation sites, and chain pairing. However, the associated patent landscape is highly complex, shaped by inconsistent mutation numbering, overlapping claims, and variable patent term extensions. This article outlines key technological strategies-ranging from Fcγ receptor and FcRn affinity modulation to antibody-drug conjugate optimization-and illustrates common intellectual property pitfalls with representative patents. Practical approaches to freedom-to-operate assessment are discussed, including reliance on expired technologies, licensing options, and layered composition-of-matter protection. Regulatory safe harbour provisions and their implications for antibody R&D are also reviewed, providing a practical guide for navigating Fc engineering patents.